Relay Therapeutics, Inc. (RLAY) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
RLAY Revenue Analysis (2018–2025)
As of February 28, 2026, Relay Therapeutics, Inc. (RLAY) generated trailing twelve-month (TTM) revenue of $15.4 million. The most recent quarter (Q4 2025) recorded $7.0 million in revenue.
Looking at the longer-term picture, RLAY's 5-year compound annual growth rate (CAGR) stands at -28.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $82.7 million in 2020.
When compared to Healthcare sector peers including INCY (+21.2% YoY), GMAB (+21.0% YoY), and EXEL (+9.9% YoY). Compare RLAY vs INCY →
Peer Comparison
Compare RLAY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RLAYCurrent | $15M | - | -28.6% | -1971.6% | |
| INCY | $5.1B | +21.2% | +14.0% | 26.1% | |
| GMAB | $21.5B | +21.0% | +32.0% | 31.1% | |
| EXEL | $2.3B | +9.9% | +18.6% | 37.6% | |
| IBRX | $15M | +1026.0% | +221.4% | -2334.2% | |
| MRUS | $35M | +55.9% | +4.7% | -753.0% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $15.4M | +53.4% | $0 | - | $-302,738,000 | -1971.6% |
| 2024 | $10.0M | -60.8% | $10.0M | 100.0% | $-372,468,000 | -3722.1% |
| 2023 | $25.5M | +1749.8% | $25.5M | 100.0% | $-373,000,000 | -1460.1% |
| 2022 | $1.4M | -54.4% | $1.4M | 100.0% | $-299,275,000 | -21670.9% |
| 2021 | $3.0M | -96.3% | $3.0M | 100.0% | $-364,698,000 | -12040.2% |
| 2020 | $82.7M | - | $79.1M | 95.7% | $-55,796,000 | -67.5% |
| 2019 | $0 | - | $-2,845,000 | - | $-84,048,000 | - |
| 2018 | $0 | - | $-2,154,000 | - | $-49,889,000 | - |
See RLAY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLAY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RLAY vs AGIO
See how RLAY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RLAY's revenue growth accelerating or slowing?
RLAY TTM revenue: $15M. YoY growth: N/A. 5-year CAGR: -28.6%.
What is RLAY's long-term revenue growth rate?
Relay Therapeutics, Inc.'s 5-year revenue CAGR of -28.6% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is RLAY's revenue distributed by segment?
RLAY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.